Phase 2 N=46 Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study
Critical Illness · Delirium · Cognitive Impairment
Primary: Number of Days Alive Without Delirium or Coma — 7.00; 8.50 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Intravenous Iron Metabolism in Restless Legs Syndrome
Restless Legs
Primary: Duration Off Treatment — 6; 3; 2; 0 participants
Phase 2 N=36 Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents
Single Ventricle Heart Disease After Fontan Surgery
Primary: Number of Subjects With Serious Adverse Events Possibly or Probably Related to Udenafil — 0; 0; 0; 0 participants
Phase 2 N=72 Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Phase 2 N=69 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
Huntington Disease
Primary: Difference in Huntington's Disease Cognitive Assessment Battery (HD-CAB) Composite Score Between Participants With HD vs HP at Baseline — -3.3657; 0.0000 Z score…
Phase 2 N=17 Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
Melanoma
Primary: Pathologic Complete Response — 9 Participants
Phase 2 N=165 Norovirus Challenge Study
Norovirus Infections
Primary: Number of Participants Who Experienced Norovirus Gastroenteritis (NVG) — 34; 37 Participants
Phase 2 N=33 Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.
Chronic Ocular Graft-versus-host Disease
Primary: Modified SANDE Questionnaire - Frequency, Change From Baseline — -22.00; -4.59 score on a scale — p=0.0197
Phase 2 N=45 Ruxolitinib in Seborrheic Dermatitis
Seborrheic Dermatitis
Primary: Number of Participants With Investigator Global Assessment of 0 or 1 at Week 4 — 20 Participants
Phase 2 N=15 A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Non Hodgkin Lymphoma · Refractory Non-Hodgkin Lymphoma · Relapsed Non Hodgkin Lymphoma
Primary: Rate of Neurotoxicity as Per CTCAE v4.03 Criteria — 3; 2; 5; 1 Participants
Phase 2 N=13 Cheese Consumption and Human Microvascular Function
Microvascular Dysfunction
Primary: Microvascular Reactivity to Acetylcholine — -4.90; -4.82; -5.44; -3.21 log (M)
Phase 2 N=80 The Role of Probiotics in HIV Patients With Immunological Non-Responder
HIV Infections · Immunological Abnormality
Primary: CD4+ Level — 162.3; 50.5; 143.3; 69.9 cell/μL — p=0.02
Phase 2 N=1 Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Measurement of Serum Lactate Dehydrogenase (LDH) — 2913; 3056; 1453; 564 U/L
Phase 2 N=32 Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome
Von Hippel-Lindau Syndrome
Primary: Overall Response Rate (Complete Response + Partial Response) — 13 Participants
Phase 2 N=125 Anti-epileptogenic Effects of Eslicarbazepine Acetate
Post Stroke Epilepsy
Primary: Proportion of Patients Who Experience the First Unprovoked Seizures (US) Within the First 6 Months After Randomisation (Failure Rate) — 2; 7; 3; 0 Participants